Covid-19 roundup: Just how much is the ‘first wave’ mar­ket for Covid-19 vac­cines worth? One top an­a­lyst sets the prize at $20B

Now that we’ve seen the US gov­ern­ment ink con­tracts on 800 mil­lion dos­es of Covid-19 vac­cine, Bern­stein’s Ron­ny Gal is ready to do the math on ex­act­ly what the glob­al mar­ket should look like in 2021.

And it isn’t cheap.

The 28 play­ers now in the race to pro­duce a Covid-19 vac­cine to end the pan­dem­ic — with the spot­light falling on the top 6 US/Eu­ro­pean com­pa­nies on the lad­der — are like­ly com­pet­ing for a slice of a $20 bil­lion “first wave” mar­ket, writes Gal. And even if 40% of the con­tract­ed vac­cine nev­er ar­rives, the US should have a line on enough shots to pro­tect 75% of the US pop­u­la­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.